This study uses the 2021 GBD dataset to analyze RHD epidemiological data in China, Asia, and globally from 1990 to 2021. It aims to provide a scientific basis for precise prevention and control strategies. The study assesses RHD incidence, prevalence, mortality, and DALYs using DisMod-MR and CODEm models and predicts future trends with Joinpoint software. Results show that global RHD incidence increased from 44.867 to 50.738 per 100,000 from 1990 to 2021, with rising prevalence but decreasing mortality and DALYs. In China, RHD cases and incidence significantly declined, with mortality dropping from 19.071 to 4.215 per 100,000 and DALYs also reduced. In Asia overall, RHD cases increased, but incidence and prevalence slightly decreased, and mortality and DALYs trended downward. Future predictions indicate that RHD incidence may rise among Chinese women but decline among men, with decreasing mortality for both genders. Recommendations include increasing government investment, enhancing early diagnosis and treatment, and mobilizing societal participation in prevention and education to reduce the global RHD burden.

Weirong Cui, Changsheng Liao, Minxiao Wang, Fangzheng He, Bin Dong. Analysis and Prediction of the Disease Burden Trend of Rheumatic Heart Disease in China, Asia, and the World from 1990 to 2021. Frontiers in Medical Science Research (2025), Vol. 7, Issue 3: 29-38. https://doi.org/10.25236/FMSR.2025.070304.

[1] Yanagawa B, Butany J, Verma S. Update on rheumatic heart disease[J]. Current opinion in cardiology, 2016, 31(2): 162-168.

[2] Berhanu H, Mekonnen Y, Workicho A, et al. The prevalence of rheumatic heart disease in Ethiopia: a systematic review and meta-analysis[J]. Tropical Diseases, Travel Medicine and Vaccines, 2023, 9(1): 16.

[3] Liu M, Lu L, Sun R R, et al. Rheumatic heart disease: causes, symptoms, and treatments[J]. Cell biochemistry and biophysics, 2015, 72: 861-863.

[4] Arvind B, Ramakrishnan S. Rheumatic fever and rheumatic heart disease in children[J]. The Indian Journal of Pediatrics, 2020, 87(4): 305-311.

[5] Marijon E, Mirabel M, Celermajer D S, et al. Rheumatic heart disease[J]. The Lancet, 2012, 379(9819): 953-964.

[6] Dougherty S, Okello E, Mwangi J, et al. Rheumatic heart disease: JACC focus seminar 2/4[J]. Journal of the American College of Cardiology, 2023, 81(1): 81-94.

[7] Rwebembera J, Beaton A Z, de Loizaga S R, et al. The global impact of rheumatic heart disease[J]. Current cardiology reports, 2021, 23: 1-10.

[8] Lv M, Jiang S, Liao D, et al. Global burden of rheumatic heart disease and its association with socioeconomic development status, 1990–2019[J]. European Journal of Preventive Cardiology, 2022, 29(10): 1425-1434.

[9] Yu G, Gong X, Xu Y, et al. The global burden and trends of four major types of heart disease, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Public Health, 2023, 220: 1-9.

[10] Guan C, Xu W, Wu S, et al. Rheumatic heart disease burden, trends, and inequalities in Asia, 1990–2019[J]. Global Health Action, 2023, 16(1): 2215011.

[11] Cui J, Guo X, Yuan X, et al. Analysis of rheumatic heart disease mortality in the Chinese population: a joinpoint and age–period–cohort study[J]. International Journal of Environmental Research and Public Health, 2022, 19(16): 9872.

[12] Vos T, Lim S S, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. The lancet, 2020, 396(10258): 1204-1222.

[13] Alvarez E M, Force L M, Xu R, et al. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. The Lancet Oncology, 2022, 23(1): 27-52.

[14] Foreman K J, Lozano R, Lopez A D, et al. Modeling causes of death: an integrated approach using CODEm[J]. Population health metrics, 2012, 10: 1-23.

[15] Lippi G, Sanchis-Gomar F, Mattiuzzi C, et al. Estimating Worldwide Impact of Low Physical Activity on Risk of Develo** Ischemic Heart Disease-Related Disability: An Updated Search in the 2019 Global Health Data Exchange (GHDx)[J]. Medicines, 2022, 9(11): 55.

[16] Chen X, Zhou C W, Fu Y Y, et al. Global, regional, and national burden of chronic respiratory diseases and associated risk factors, 1990–2019: Results from the Global Burden of Disease Study 2019[J]. Frontiers in medicine, 2023, 10: 1066804.

[17] Wang M, Jiang Z, You M, et al. An Autoregressive Integrated Moving Average Model for Predicting Varicella Outbreaks—China, 2019[J]. China CDC Weekly, 2023, 5(31): 698.

[18] Ilu S Y, Prasad R. Improved autoregressive integrated moving average model for COVID-19 prediction by using statistical significance and clustering techniques[J]. Heliyon, 2023, 9(2).

[19] Li Y, Liu X, Li X, et al. Interruption time series analysis using autoregressive integrated moving average model: evaluating the impact of COVID-19 on the epidemic trend of gonorrhea in China[J]. BMC Public Health, 2023, 23(1): 2073.

[20] Murray C J L. The global burden of disease study at 30 years[J]. Nature medicine, 2022, 28(10): 2019-2026.

[21] Wu A M, Bisignano C, James S L, et al. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019[J]. The Lancet Healthy Longevity, 2021, 2(9): e580-e592.

[22] Wang R, Li Z, Liu S, et al. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019[J]. BMJ open, 2023, 13(3): e065186.

[23] Kim H J, Fay M P, Feuer E J, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Statistics in medicine, 2000, 19(3): 335-351.

[24] Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer communications, 2021, 41(10): 1037-1048.

[25] Shi L, Bao C, Wen Y, et al. Analysis and comparison of the trends in burden of rheumatic heart disease in China and worldwide from 1990 to 2019[J]. BMC Cardiovascular Disorders, 2023, 23(1): 517.

[26] Noubiap J J, Agbor V N, Bigna J J, et al. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies[J]. Scientific reports, 2019, 9(1): 17022.

[27] Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart disease in Africa: The Addis Ababa communiqué: Cardiovascular topics[J]. Cardiovascular journal of Africa, 2016, 27(3): 184-187.

[28] Ruan R, Liu X, Zhang Y, et al. Global, regional, and national advances toward the management of rheumatic heart disease based on the Global Burden of Disease Study 2019[J]. Journal of the American Heart Association, 2023, 12(13): e028921.

[29] Belguith A S, Abdelkafi A K, El Mhamdi S, et al. Rheumatic heart disease in a develo** country: incidence and trend (Monastir; Tunisia: 2000–2013)[J]. International journal of cardiology, 2017, 228: 628-632.

[30] Carapetis J R. The stark reality of rheumatic heart disease[J]. European heart journal, 2015, 36(18): 1070-1073.

[31] Rothenbühler M, O'Sullivan C J, Stortecky S, et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents[J]. The Lancet Global Health, 2014, 2(12): e717-e726.

[32] Zühlke L J, Engel M E, Watkins D, et al. Incidence, prevalence and outcome of rheumatic heart disease in South Africa: a systematic review of contemporary studies[J]. International journal of cardiology, 2015, 199: 375-383.

[33] Remenyi B, Carapetis J, Wyber R, et al. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease[J]. Nature Reviews Cardiology, 2013, 10(5): 284-292.

[34] Vervoort D, Yilgwan C S, Ansong A, et al. Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summary[J]. BMJ global health, 2023, 8(Suppl 9): e012355.

[35] Palafox B, Mocumbi A O, Kumar R K, et al. The WHF roadmap for reducing CV morbidity and mortality through prevention and control of RHD[J]. Global heart, 2017, 12(1): 47-62.